INVICTUS trial: positive results for patients with GIST

Ripretinib as fourth-line therapy showed to improve progression-free survival in patients with advanced gastrointestinal stromal tumours (GIST) in the phase III INVICTUS trial presented today. According to Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland,…

Watch Here

‘A train to ESMO’ for the climate

Achieving a sustainable cancer care in a sustainable world. This is the idea that moved Dr Joakim Crona from the University Hospital Uppsala Akademiska Sjukhuset, Sweden, to run an initiative – ‘A train to ESMO’…

Watch Here